Stibbe advises Mylan

Matter
EU Law
Expertise
Healthcare and Life Sciences Tax EU and Competition Law Corporate and M&A Civil-Law Notary

Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda.

Car in motion at dusk with headlights illuminating the street

The combination of Mylan and Meda will create a diversified global pharmaceutical leader with an expansive portfolio of branded and generic medicines and a strong and growing portfolio of over-the-counter (OTC) products.

Key contact(s)

Team